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Nonesterified fatty acids (NEFA) play pathophysiological roles in metabolic syndrome and
type 2 diabetes (T2D). In this study, we analyzed the fasting NEFA profiles of normoglyce-
mic individuals at risk for T2D (women with a recent history of gestational diabetes (GDM))
in comparison to controls (women after a normoglycemic pregnancy). We also examined
the associations of NEFA species with overweight/obesity, body fat distribution and insulin
sensitivity.
Subjects and Methods
Using LC-MS/MS, we analyzed 41 NEFA species in the fasting sera of 111 women (62
post-GDM, 49 controls). Clinical characterization included a five-point oral glucose toler-
ance test (OGTT), biomarkers and anthropometrics, magnetic resonance imaging (n = 62)
and a food frequency questionnaire. Nonparametric tests with Bonferroni correction, binary
logistic regression analyses and rank correlations were used for statistical analysis.
Results
Women after GDM had a lower molar percentage of total saturated fatty acids (SFA;
38.55% vs. 40.32%, p = 0.0002) than controls. At an explorative level of significance several
NEFA species were associated with post-GDM status (with and without adjustment for body
mass index (BMI) and HbA1c): The molar percentages of 14:0, 16:0, 18:0 and 18:4 were
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reduced, whereas those of 18:1, 18:2, 20:2, 24:4, monounsaturated fatty acids (MUFA),
polyunsaturated fatty acids (PUFA) and total n-6 NEFA were increased. BMI and the
amount of body fat correlated inversely with several SFA and MUFA and positively with vari-
ous PUFA species over the whole study cohort (abs(ρ)0.3 for all). 14:0 was inversely and
BMI-independently associated with abdominal visceral adiposity. We saw no correlations of
NEFA species with insulin sensitivity and the total NEFA concentration was similar in the
post-GDM and the control group.
Conclusion
In conclusion, we found alterations in the fasting NEFA profile associated with a recent his-
tory of gestational diabetes, a risk marker for T2D. NEFA composition also varied with over-
weight/obesity and with body fat distribution, but not with insulin sensitivity.
Introduction
Several lines of evidence suggest that NEFA are involved in the pathogenesis of T2D via a re-
duction of insulin sensitivity and the promotion of pancreatic beta cell apoptosis and dysfunc-
tion [1–3]. Particularly in the context of metabolic syndrome, NEFA might represent an
important link between obesity and insulin resistance [4, 5]. However, it is not entirely clear
whether elevated serum NEFA levels in individuals with T2D or metabolic syndrome are a pri-
mary disease-inducing alteration or a secondary change [6, 7].
Different NEFA species have distinct effects on insulin sensitivity, beta cell function and
tissue inflammation in experimental setups [8]. SFA, for instance, are able to interact with
toll-like receptor 4 (TLR-4) to induce proinflammatory signaling [9], whereas PUFA, such as
docosahexaenoic acid (22–6 n-3), inhibit these pathways, e.g., by binding to G protein-coupled
receptor 120 [10].
Previous studies have shown differences in the serum NEFA composition between individu-
als with T2D or metabolic syndrome and controls [11, 12]. We wanted to test the hypothesis
that the serum NEFA profile is also altered in a specific cohort of young, normoglycemic indi-
viduals with a high risk for T2D, namely in women after GDM.We chose a recent history of
GDM to select the at-risk cohort because no reliable biomarkers are available to identify T2D
at-risk subjects while they are still normoglycemic. Women with GDM during a recent preg-
nancy however have an about 10-fold increased risk for subsequent T2D within 10 years and
therefore represent a suitable population to address our research question [13, 14]. Women
after a normoglycemic pregnancy were included in the study as controls. We also examined the
associations of the fasting NEFA profile with body fat distribution and insulin resistance.
Subjects and Methods
Study population
Between November 2011 and December 2013 147 women were consecutively recruited within
the prospective Prediction, Prevention and Subclassification of Type 2 Diabetes (PPS-Diab) co-
hort study [15]. Gestational diabetes and normoglycemia during pregnancy were diagnosed
with a 75g OGTT between the 24th and the 28th week of gestation following the IADPSG crite-
ria [16]. For this analysis, 111 women (62 cases after GDM and 49 controls) were included due
to normoglycemia at the baseline visit between 3 and 16 months after delivery. Over 90% of the
Serum Nonesterified Fatty Acids in Women Post Gestational Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0128001 May 26, 2015 2 / 13
study participants were Caucasian. Exclusion criteria for this study were chronic diseases re-
quiring medication except for hypothyroidism. Hormonal contraception was also permitted.
Written informed consent was obtained from each subject and the study was approved by the
ethics committee of the Ludwig-Maximilians-Universität München.
Anthropometric and clinical measurements
Weight and fat mass were measured using a bioelectrical impedance analysis (BIA) scale
(Tanita BC-418, Tanita Corporation, Tokyo, Japan). BMI was calculated as the weight (in kilo-
grams) divided by height squared (in meters). Hip and waist circumferences (WC) were as-
sessed by tape measurements. Daily physical activity (m/d) was measured by a pedometer
(AiperMotion 440, Aipermon GmbH & Co. KG, Munich, Germany). A 5-point 75 g OGTT
was performed once. Normoglycemia was defined as fasting blood glucose<100mg/dl and
2 hour blood glucose<140mg/dl. During the OGTT, blood pressure readings were obtained
three times from all subjects in a sitting position. A food frequency questionnaire (EPIC-FFQ)
for the assessment of dietary nutritional intake was completed online by the majority of the
study participants (n = 87) [17]. In a subgroup of women (n = 62, consisting of 37 cases and
25 controls) whole body fat and abdominal subcutaneous and visceral fat were measured with
an axial T1w or mDixon magnetic resonance imaging (MRI) technique [18] on a 3.0 Tesla
scanner (Philips Healthcare, Best, The Netherlands). Liver fat was assessed with fat fraction
maps generated from mDixon sequences [19].
Blood sample collection and analysis
Analysis of serum NEFA. After 30 minutes of coagulation time, serum monovettes were
centrifuged at 2000 g at room temperature. Serum aliquots were then immediately frozen on
dry ice and stored at -80°C until analysis. The total NEFA concentrations were determined by
an enzymatic calorimetric method (NEFA Kit, Wako Chemicals, Neuss, Germany). For quanti-
fication of the NEFA species, 20 μl of each serum sample was mixed with 200 μl isopropanol
(containing the internal standard) in a 96-deepwell plate. After centrifugation, the supernatant
was used for NEFA analysis by LC-MS/MS as previously described [20]. The NEFA were iden-
tified according to chain length and the number of double bonds. The positions of double
bonds were estimated by the relative frequency of the isomeric NEFA in the fasting human
blood [21]. Forty-one out of 47 NEFA fulfilled the quality control criteria that the coefficients
of variation (CV) were below 20% for all measurements. Serum NEFA concentrations were cal-
culated as molar percentages of the total NEFA [21]. Enzyme activities were estimated by the
following ratios of products to substrates: 18:1/18:0 for stearoyl CoA desaturase-1 (SCD-1),
18:0/16:0 for elongation of very long chain fatty acids protein 6 (EloVL6), and 20:4/20:3 for
delta-5-desaturase (Δ-5 D).
Laboratory measurements and calculations. Serum insulin was measured with chemilu-
minescence technology (CLIA, DiaSorin LIAISON systems, Saluggia, Italy). Glucose concen-
trations from sodium fluoride plasma were determined using a glucose analyzer (with the
glucose oxidase method, Glucose HK Gen.3, Roche Diagnostics, Mannheim, Germany). The
following additional laboratory parameters were analyzed: HbA1c (VARIANT II TURBO
HbA1c Kit—2.0, Bio-Rad Laboratories, Hercules, USA), hsCRP (wide-range CRP, Siemens
AG, Erlangen, Germany), gamma-GT (enzymatic caloric test, Roche Diagnostics), triglycerides
(enzymatic caloric test, Roche Diagnostics), cholesterol (enzymatic caloric test, Roche Diagnos-
tics), HDL (enzymatic caloric test, Roche Diagnostics), and LDL was calculated with the Frie-
dewald equation (all triglyceride levels were below 400 mg/dl).
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The following protein mediators were measured in plasma samples: fetuin-A (ELISA, Bio-
Vendor, Heidelberg, Germany), leptin (ELISA "Dual Range", Merck Millipore, Darmstadt, Ger-
many), adiponectin (RIA, Merck Millipore), and resistin (Quantikine ELISA, R&D Systems,
Wiesbaden-Nordenstadt, Germany).
The Matsuda Index was calculated as described previously [22] and used to quantify insulin
sensitivity. Additionally, the HOMA-IR was assessed as the product of fasting glucose and fast-
ing insulin concentrations, and the adipocyte insulin resistance (Adipocyte-IR) index was cal-
culated as the product of fasting total NEFALC-MS/MS and fasting insulin concentrations [23,
24]. The disposition index was calculated from the OGTT to measure the relationship between
insulin sensitivity and first-phase insulin secretion [25]. The rise in serum insulin during the
first 30 minutes of the OGTT was used as a measure of the first-phase insulin secretion. The
correlation of this measure with the first-phase secretion in the IVGTT was significantly better
than that of the insulinogenic index in a substudy of the PPS-Diab study [15].
Statistical analyses
The statistical analyses were performed with SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). All
numeric values are reported as median (first and third quartile) because the majority of the pa-
rameters were not normally distributed. Mann-Whitney U tests or a Chi-Square test were used to
assess group differences. Multiple comparisons of the NEFAmeasurements were accounted for
by Bonferroni correction. Those significant NEFAmeasurements from theMann-Whitney U
tests were further analyzed together with clinical parameters as independent variables by binary
logistic regression models for the dependent variable pGDM status. The correlations between
metric variables were calculated with Spearman's rank correlation coefficients (ρ) and with partial
Spearman's rank correlation coefficients (ρ) with adjustment for BMI or total body fat volume. A
p-value<0.05 was considered statistically significant. After Bonferroni correction alpha = 9.62e-4.
Results
Baseline characteristics
We included 62 normoglycemic women after a pregnancy complicated by GDM and 49 con-
trols after a normoglycemic pregnancy in this analysis. The time from delivery to study inclu-
sion was 3–16 months. The baseline characteristics of the study subjects are shown in Table 1.
The Matsuda Index of insulin sensitivity and the Disposition Index were lower among the
women after GDM (p = 0.030 and p = 0.002, respectively), but the HOMA-IR and the Adipo-
cyte-IR Index were not different between the groups. Although all of the study subjects were
normoglycemic, the glucose concentrations were significantly higher at each time point of the
OGTT in post-GDM group. Metabolic risk factors such as triglycerides, HDL, hsCRP, gamma-
GT, BMI, body fat percentage by bioimpedance measurement andWC were similar in the two
groups. In an MRI substudy (n = 62), we also found no significant differences in total body fat
volume, abdominal visceral fat volume and liver fat content. The hepatokine fetuin-A was sig-
nificantly elevated in women after GDM (p = 0.008), but the serum concentrations of the adi-
pokines leptin, adiponectin and resistin were not different (Table 2). There were also no
significant differences in macronutrient consumption, as estimated by a food frequency ques-
tionnaire (EPIC-FFQ; S1 Table).
Serum NEFA composition in women after GDM and controls
Total fasting NEFA concentrations did not differ between the women after GDM and controls
(564.5 μM (407.0 μM—668.0 μM) vs. 548.0 μM (444.0 μM—681.0 μM), Table 3). The
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enzymatic measurement of serum NEFA and the calculated sum of all NEFA species as quanti-
fied by LC-MS/MS produced similar results (ρ = 0.86, p<0.001).
We were able to quantify 41 NEFA species by LC-MS/MS (Table 3). Monounsaturated fatty
acids (MUFA) (46.4% (44.2%–47.8%) were predominantly present in fasting serum followed
by SFA (39.5% (37.9%–40.8%) and PUFA (13.8% (13.0%–15.0%). The most abundant NEFA
species were oleic acid (18:1 n-9), palmitic acid (16:0), linoleic acid (18:2 n-6) and stearic acid
(18:0).
Table 1. Clinical and biochemical characteristics of the study cohort.
post-GDM controls p-value
Clinical characteristics
Months post-delivery 8.95 (7.50–11.60) 8.80 (7.00–10.30) 0.213
Hormonal contraception n (%)* 7 (11.3) 12 (24.5) 0.067
Age (years) 35 (32–38) 35 (32–37) 0.903
BMI (kg/m2) 23.2 (21.4–26.6) 22.7 (21.3–25.9) 0.297
WC (cm) (n = 58/49) # 78 (73–86) 75 (71–83) 0.247
Waist to hip ratio (n = 58/49) # 0.80 (0.76–0.86) 0.80 (0.75–0.84) 0.277
Body fatBIA (%) (n = 62/48)
# 29.75 (25.70–37.70) 30.60 (26.20–35.20) 0.861
Systolic blood pressure (mmHg) 119 (112–125) 115 (107–123) 0.063
Diastolic blood pressure (mmHg) 75 (70–79) 72 (64–81) 0.068
Distance (m/d) (n = 41/41) # 6610 (5104–8407) 6838 (5114–8259) 0.597
MRI substudy (n = 37/25) #
Total fatMRI (l) 20.25 (16.46–29.40) 19.65 (16.88–24.26) 0.571
Visceral fatMRI
a (l) 1.68 (1.13–2.84) 1.34 (1.01–1.91) 0.134
Subcutaneous fatMRI
a (l) 5.73 (4.12–8.29) 5.61 (4.31–6.72) 0.605
Liver fat (%) 0.51 (0.18–1.27) 0.41 (0.09–0.66) 0.137
Biochemical characteristics
Matsuda Index 5.35 (3.68–8.02) 6.67 (4.84–8.51) 0.030
HOMA-IR 1.44 (0.94–2.35) 1.22 (0.81–1.91) 0.148
Adipocyte-IR Indexb 3353 (1760–5496) 2901 (1911–4116) 0.290
Disposition Index 235.67 (176.73–303.60) 303.21 (244.65–368.26) 0.002
Fasting plasma glucose (mg/dl) 91 (87–95) 90 (83–92) 0.026
30min. plasma glucose (mg/dl) 151 (129–170) 140 (121–154) 0.016
60min. plasma glucose (mg/dl) 137 (113–163) 117 (99–132) 0.001
90min. plasma glucose (mg/dl) 111 (97–136) 100 (89–113) 0.005
2 hour plasma glucose (mg/dl) 112 (96–120) 94 (82–110) <0.001
Triglyceride (mg/dl) 65 (51–89) 63 (50–87) 0.955
HDL (mg/dl) 64 (51–72) 64 (57–74) 0.570
LDL (mg/dl) 104 (89–115) 108 (97–123) 0.057
hsCRP (mg/dl) 0.06 (0.02–0.32) 0.04 (0.01–0.11) 0.252
Gamma-GT (U/l) 14 (12–19) 14 (11–18) 0.858
HbA1c (%) 5.4 (5.3–5.6) 5.3 (5.1–5.5) 0.033
HbA1c (mmol/mol) 35.5 (34.4–37.7) 34.4 (32.2–36.6) 0.033




bAdipocyte-IR Index = fasting total NEFALC-MS/MS (μM) * fasting insulin (μU/ml).
doi:10.1371/journal.pone.0128001.t001
Serum Nonesterified Fatty Acids in Women Post Gestational Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0128001 May 26, 2015 5 / 13
At an exploratory level of significance (p<0.05) we found the following differences in the
molar percentages of the various NEFA species in the post-GDM group compared to the con-
trols: 12:0, 14:0, 16:0, 18:0, 26:0, and total SFA were reduced, and 18:1, 18:2, MUFA, total n-6
NEFA and the proportion of total n-6/n-3 NEFA were increased (Table 3, Fig 1). Cases also
showed a higher calculated SCD-1 activity (4.70 vs. 4.21, p = 0.010, Table 3), but no changes in
EloVL6 or Δ-5 D activities. All differences remained significant with adjustment for BMI and
HbA1c, except for 12:0 and 26:0.
After Bonferroni correction for multiple testing, only total SFA were still significantly differ-
ent between women after GDM and controls (38.6% vs. 40.3%, p = 0.0002). Total serum SFA
were unrelated to the daily dietary intake of these fatty acids estimated from the EPIC-FFQ (S2
Table). We also did not observe a significant correlation with BMI, but found a negative associ-
ation between SFA and estimated SCD-1 activity (ρ = -0.80, p<0.001).
Associations of NEFA species with body composition and insulin
resistance
We examined the associations between the different NEFA species and clinical parameters of
body composition (BMI, WC) as well as total body fat and abdominal visceral adipose tissue
from the MRI substudy. The group of women after GDM and the control group were com-
bined for this analysis. All NEFA species with at least one association with a Spearman ρ0.3
are shown in Table 4. 16:3, 18:2, 22:4, 26:2 and 26:3 were positively associated with BMI and all
other parameters of body fat, whereas 12:0, 14:0, 15:0, 20:0, 15:1, and 20:1 showed negative cor-
relations. With respect to visceral adipose tissue, 14:0 and partially 12:0 remained significantly
and inversely associated with WC and abdominal visceral adiposity after adjustment for BMI
and total body fat, respectively (Table 4). The associations of NEFA species with measures of
adiposity were similar in women after GDM and controls, when we repeated the analyses sepa-
rately in the two groups (data not shown). We observed no relevant correlations with a Spear-
man ρ0.3 of single NEFA species and insulin sensitivity (Matsuda Index).
Associations of essential fatty acids with dietary intake
Linoleic acid (18:2 n-6) and linolenic acid (18:3 n-3) are the only two fatty acids that cannot be
synthesized endogenously. Over the whole study cohort, dietary intakes of 18:2 and 18:3 corre-
lated with plasma levels of these fatty acids (ρ = 0.33, p = 0.002 and ρ = 0.23, p = 0.029, respec-
tively). Furthermore, the sum of serum PUFA correlated with estimated PUFA intake (g/day)
(ρ = 0.36, p = 0.001, S2 Table).
Discussion
The main findings of this study are that in the fasting state the total serum NEFA concentration
was similar in normoglycemic women with recent GDM and controls, but that differences
Table 2. Plasma concentrations of selected biomarkers.
post-GDM controls p-value
Fetuin-A (μg/ml) 288.35 (266.60–312.00) 263.40 (242.20–295.40) 0.008
Leptin (ng/ml) 8.73 (5.07–13.68) 6.89 (2.93–11.56) 0.071
Adiponectin (μg/ml) 9.99 (7.71–16.37) 11.63 (9.32–14.61) 0.512
Resistin (ng/ml) 8.52 (7.18–10.65) 8.90 (7.54–10.86) 0.845
The values are represented as the medians with interquartile ranges.
doi:10.1371/journal.pone.0128001.t002
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Table 3. Fasting serumNEFA profiles and total NEFA concentrations.
post-GDM controls p-value* BMI and HbA1c adj. p-value**
12:0 0.744% (0.595%-0.902%) 0.809% (0.720%-1.018%) 0.008 0.059
13:1 0.047% (0.034%-0.056%) 0.048% (0.039%-0.059%) 0.525
14:0 3.013% (2.584%-3.457%) 3.346% (2.779%-3.775%) 0.034 0.030
14:1 0.617% (0.516%-0.720%) 0.607% (0.519%-0.755%) 0.913
14:2 0.051% (0.043%-0.065%) 0.049% (0.043%-0.057%) 0.392
15:0 0.495% (0.426%-0.596%) 0.542% (0.457%-0.598%) 0.238
15:1 0.043% (0.036%-0.051%) 0.046% (0.038%-0.052%) 0.538
16:0 25.112% (23.938%-25.857%) 25.615% (24.757%-26.314%) 0.014 0.004
16:1 5.338% (4.519%-6.021%) 4.982% (4.210%-5.781%) 0.230
16:2 0.074% (0.066%-0.079%) 0.071% (0.062%-0.081%) 0.373
16:3 0.026% (0.022%-0.031%) 0.026% (0.022%-0.029%) 0.723
17:0 0.522% (0.473%-0.581%) 0.555% (0.507%-0.590%) 0.202
17:1 0.357% (0.323%-0.387%) 0.342% (0.320%-0.394%) 0.553
18:0 8.482% (7.664%-9.242%) 9.036% (8.410%-9.865%) 0.034 0.033
18:1 39.483% (38.272%-41.091%) 39.069% (37.352%-40.055%) 0.040 0.019
18:2 11.065% (10.236%-12.172%) 10.401% (9.865%-11.326%) 0.034 0.019
18:3 1.177% (1.031%-1.345%) 1.145% (1.071%-1.322%) 0.941
18:4 0.025% (0.019%-0.032%) 0.028% (0.024%-0.036%) 0.077
19:0 0.050% (0.044%-0.057%) 0.053% (0.046%-0.057%) 0.360
19:1 0.136% (0.127%-0.150%) 0.141% (0.126%-0.155%) 0.658
20:0 0.055% (0.048%-0.068%) 0.058% (0.051%-0.070%) 0.127
20:1 0.349% (0.317%-0.398%) 0.344% (0.313%-0.387%) 0.517
20:2 0.194% (0.169%-0.216%) 0.183% (0.166%-0.201%) 0.069
20:3 0.215% (0.187%-0.234%) 0.208% (0.188%-0.232%) 0.931
20:4 0.760% (0.616%-0.935%) 0.774% (0.617%-0.932%) 0.950
20:5 0.089% (0.071%-0.114%) 0.090% (0.074%-0.108%) 0.739
22:2 0.007% (0.006%-0.008%) 0.007% (0.006%-0.007%) 0.239
22:3 0.010% (0.009%-0.011%) 0.010% (0.009%-0.011%) 0.890
22:4 0.086% (0.077%-0.097%) 0.081% (0.071%-0.091%) 0.086
22:5 0.180% (0.163%-0.202%) 0.183% (0.164%-0.204%) 0.766
22:6 0.415% (0.359%-0.511%) 0.441% (0.345%-0.537%) 0.515
24:0 0.024% (0.021%-0.030%) 0.027% (0.021%-0.032%) 0.262
24:1 0.041% (0.034%-0.049%) 0.040% (0.034%-0.047%) 0.677
24:3 0.002% (0.001%-0.002%) 0.002% (0.001%-0.002%) 0.442
24:4 0.005% (0.005%-0.006%) 0.005% (0.004%-0.005%) 0.071
24:5 0.007% (0.005%-0.008%) 0.006% (0.006%-0.008%) 0.928
24:6 0.005% (0.004%-0.006%) 0.006% (0.005%-0.007%) 0.180
26:0 0.002% (0.002%-0.004%) 0.003% (0.002%-0.004%) 0.048 0.979
26:1 0.006% (0.005%-0.007%) 0.006% (0.005%-0.007%) 0.901
26:2 0.008% (0.007%-0.011%) 0.008% (0.006%-0.011%) 0.517
26:3 0.003% (0.002%-0.004%) 0.003% (0.002%-0.004%) 0.633
SFA 38.547% (36.940%-39.937%) 40.323% (38.769%-41.630%) <0.001# <0.001
MUFA 46.655% (45.006%-48.549%) 45.972% (43.697%-47.010%) 0.011 0.014
PUFA 14.699% (13.652%-15.906%) 13.974% (13.295%-15.146%) 0.059
∑ n-3 1.952% (1.733%-2.208%) 1.954% (1.801%-2.184%) 0.563
∑ n-6 12.325% (11.493%-13.775%) 11.792% (11.004%-12.841%) 0.033 0.015
n-6/n-3 6.435% (5.819%-7.130%) 6.117% (5.283%-6.806%) 0.020 0.045
(Continued)
Serum Nonesterified Fatty Acids in Women Post Gestational Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0128001 May 26, 2015 7 / 13
between the groups existed in the NEFA composition. Women after GDM had a lower propor-
tion of SFA and, at an exploratory level of significance, higher proportions of linoleic acid (18:2
n-6) and total n-6 NEFA. These differences were unchanged after adjustment for BMI and
HbA1c. In a combined analysis of all study participants we also found positive as well as nega-
tive associations of several NEFA species with overweight/obesity. 14:0 and partially also 12:0
were inversely associated with abdominal visceral adiposity after adjustment for total body fat.
Women after GDM have an at least 10-fold increased risk of developing T2D later in life
but are normoglycemic early after the index pregnancy in most cases [14]; thus, this population
provides a unique opportunity to study an at-risk phenotype for T2D under normoglycemic
conditions. This predisposition for T2D was also visible in our cross sectional data. Although
the distributions of BMI, fat mass, liver fat, blood pressure, triglycerides and HDL/LDL choles-
terol of the post-GDM group were similar to those of controls, the Matsuda Index and the Dis-
position Index were both significantly decreased. Hence, reduced insulin sensitivity and
impaired beta-cell function were already present in these normoglycemic at-risk subjects.
Fasting serum NEFA are not directly derived from nutritional intake but primarily originate
from adipose tissue storages [26, 27]. Thus, the association between the fatty acid composition
of the adipose tissue and the NEFA profile in the fasting serum is strong [28]. Adipose tissue
fatty acids are long-term markers of dietary fatty acid intake [21, 29] but also result from enzy-
matic modifications. Primarily, elongases and desaturases as well as enzymes involved in oxida-
tion pathways affect fatty acid composition. The fatty acid-modifying enzymes for which
connections to insulin resistance and T2D have been shown include delta-5, delta-6 and delta-
9 desaturases (SCD-1) and elongase EloVL6 [30, 31]. SCD-1 is of particular interest because it
is the rate-limiting step in the transformation of proinflammatory SFA to MUFA [32, 33].
The significant difference in the SFA proportion between women after GDM and controls
that we observed was small (median 38.6% vs. 40.3%) but independent of BMI and HbA1c. Its
biological relevance nevertheless remains uncertain. Our results suggest that the lower propor-
tion of SFA in the post-GDM group was caused by endogenous transformation of SFA to
MUFA and not by different nutritional intake. However, it is possible that the food frequency
questionnaire did not adequately represent all aspects of fatty acid intake. Nevertheless the cal-
culated activity of SCD-1 was elevated in the women after GDM and inversely correlated with
the SFA proportion. Our approach to estimate SCD-1 activity has been shown to reflect subcu-
taneous adipose tissue SCD-1 expression [34]. We previously showed that elevated plasma
fetuin-A, a predictive biomarker for T2D [35, 36], is also an independent risk marker in
women with a recent history of GDM [15]. This finding was replicated in the present study.
Table 3. (Continued)
post-GDM controls p-value* BMI and HbA1c adj. p-value**
SCD-1 (18:1/18:0) 4.697 (4.164–5.317) 4.205 (3.908–4.747) 0.010 0.013
EloVL6 (18:0/16:0) 0.341 (0.315–0.373) 0.346 (0.318–0.384) 0.329
Δ-5 D (20:4/20:3) 3.720 (3.058–4.314) 3.554 (3.253–4.119) 0.917
Total NEFALC-MS/MS 485.1 μM (402.8 μM -622.4 μM) 485.42 μM (408.1 μM -594.0 μM) 0.981
Total NEFAEnzymatic Test 564.5 μM (407.0 μM -668.0 μM) 548.0 μM (444.0 μM -681.0 μM) 0.805
Percentage concentrations (mol%) and absolute concentrations of NEFA are given as medians with interquartile ranges. n = 62 for the cases and n = 49
for the controls.
*Mann-Whitney U tests.
**Logistic regression analyses were adjusted for BMI and HbA1c when p<0.05 from Mann-Whitney U test.
#Significant after Bonferroni correction.
doi:10.1371/journal.pone.0128001.t003
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Since fetuin-A co-signals with SFA to induce adipose tissue inflammation [37], one possible ex-
planation for the lower SFA proportions in normoglycemic women after GDM is that this con-
stitutes a compensatory response to higher fetuin-A concentrations. However, at this point this
remains speculative.
At an exploratory level of significance we also found higher levels of the essential fatty acid
linoleic acid (18:2 n-6) and total n-6 NEFA in the post-GDM group. These NEFA species are
linked to inflammatory signaling, insulin resistance and T2D risk [38, 39]. Nutritional advice
for a 18:2-poor diet might therefore have the beneficial effect of less arachidonic acid (20:4 n-6)
production and anti-inflammatory eicosanoid synthesis [40] in individuals at risk for T2D, in
particular in women with GDM.
Correlations between distinct saturated fatty acids including 12:0, 14:0 and 18:0 and insulin
sensitivity were previously shown in 70 year old men with established T2D by Iggman et al.
Fig 1. Altered NEFA pathways in cases compared to controls. At an exploratory level of significance (p<0.05), the women after GDM exhibited reduced
levels of 12:0, 14:0, 16:0, 18:0, 26:0 and total SFA and elevated levels of 18:1, the essential fatty acid 18:2, total n-6 NEFA and the proportion of total n-6/n-3
NEFA. Calculated SCD-1 activity was significantly increased in the post-GDM group. Only total SFA remained significantly different after Bonferroni
correction. The red arrows in the diagram represent upregulation, and the blue arrows represent downregulation in the post-GDM group.
doi:10.1371/journal.pone.0128001.g001
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[41]. We were unable to reproduce these observations, probably due to the different study pop-
ulations. We found that the saturated fatty acids 12:0, 14:0, 15:0, 20:0, as well as the monoun-
saturated fatty acids 15:1 and 20:1, were inversely correlated with BMI and other parameters of
adiposity in our study. 16:3, 18:2, 22:4, 26:2 and 26:3 showed positive correlations. These BMI-
associated changes in the fasting serum NEFA might be related to pathologic alterations of the
adipose tissue in obesity, e.g. adipocyte hypertrophy [42]. The SFA 14:0 and to a lesser extent
12:0 were particularly interesting with respect to body composition because they showed an in-
verse association with visceral adiposity in a BMI-independent manor. A low serum concentra-
tion of 14:0 has recently also been identified as a biomarker of T2D [43]. This link may be
explained by the inverse association of 14:0 with visceral obesity that we saw in our analysis.
The major strength of our study is the consecutively recruited, normoglycemic cohort of
young women with very few confounding diseases or medications. Limitations include the
cross-sectional study design, which precludes propositions about causality and the prognostic
relevance of our findings. Cohort size also limited the statistical power of some of our analyses.
We also cannot exclude the possibility that our findings in part represent changes that are in-
duced by the prior GDM or its treatment. However, nutritional information collected by food
frequency questionnaire showed no differences between the post-GDM and the control group.
Finally, it is unclear to what extent findings from a cohort of young women can be transferred
to the general population.
In conclusion, this study shows differences in the fasting serum NEFA profile between
women with a recent history of GDM, i.e. a high risk group for T2D, and control subjects. The
NEFA composition also varied with overweight/obesity but not with insulin sensitivity. These
findings are probably only in part related to fatty acid intake and mostly the result of enzymatic
modifications. Our data should be confirmed in larger clinical cohorts and experimental evi-
dence will be required to test their pathophysiological relevance.
Table 4. Spearman correlation coefficients of selected fasting serumNEFA species with parameters of body composition.
BMI Body
fatBIA






Abdominal fat volume (adjusted for
total fat volume, MRI)
12:0 -0.323*** -0.355*** -0.424*** -0.305** -.225 -0.272* -0.156
14:0 -0.372*** -0.417*** -0.480*** -0.340*** -0.473*** -0.533*** -0.290*
15:0 -0.206* -0.279** -0.273** -0.192 -0.340** -0.296* -0.041
15:1 -0.202* -0.244* -0.278** -0.209* -0.256* -0.314* -0.188
16:3 0.287** 0.326*** 0.290** 0.089 0.340** 0.285* 0.021
18:2 0.236* 0.210* 0.244* 0.083 0.285* 0.345** 0.202
20:0 -0.392*** -0.414*** -0.353*** -0.032 -0.451*** -0.363** -0.001
20:1 -0.238* -0.216* -0.233* -0.055 -0.340** -0.308* -0.062
22:4 0.312** 0.336*** 0.343*** 0.154 0.392** 0.412*** 0.176
26:2 0.273** 0.326*** 0.323*** 0.178 0.342** 0.315* 0.072
26:3 0.297** 0.360*** 0.386*** 0.269** 0.261* 0.263* 0.093
All nonesterified fatty acid (NEFA) species with a Spearman correlation coefficient ρ0.3 with any of the listed parameters of body composition are shown
in the table. The post-GDM and the control group were combined for this analysis. n = 106 for BMI, WC and percent body fat measured by BIA. n = 62 for
the MRI substudy.
*Correlation is significant with p<0.05.
**Correlation is significant with p<0.01.
***Correlation is significant with p<0.001.
doi:10.1371/journal.pone.0128001.t004
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